Viloxazine
QELBREE
Serotonin-Norepinephrine Modulating AgentGeneric available
The mechanism of action of viloxazine in the treatment of ADHD is unclear; however, it is thought to be through inhibiting the reuptake of norepinephrine.
Compare Viloxazine →FDA-Approved Indications
- Attention-deficit/hyperactivity disorder (adults; pediatric 6+)
Common Off-Label Uses
- Anxiety disorders (with ADHD)
What Sets This Drug Apart
- Newest FDA-approved non-stimulant for ADHD (Qelbree); selective NRI with serotonin modulation — mechanism more complex than traditional NRIs
- FDA-approved for ADHD in children 6+ and adults; NOT scheduled, no abuse potential
- Moderate CYP1A2 inhibitor — significant drug interaction burden with CYP1A2 substrates (tizanidine, theophylline, caffeine sensitivity)
- Enhances prefrontal dopamine via NET inhibition in areas where dopamine is inactivated by NET (no DAT present); not a direct DAT inhibitor
- GI side effects (nausea, vomiting) are the most common tolerability issues, particularly during titration
Boxed Warning
SUICIDAL THOUGHTS AND BEHAVIORS